Trials / Completed
CompletedNCT01611545
Pharmacogenomics and Effective Treatment With Clopidogrel
Can Pharmacogenomic Testing Improve Response and Avoid Adverse Effects With Clopidogrel Therapy? A Biospecimen Bank for Genetic and Genomic Investigation of Clopidogrel.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 130 (actual)
- Sponsor
- Avera McKennan Hospital & University Health Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this biospecimen repository is to evaluate an individual's genotype, identify the variances, and understand how they relate to treatment with clopidogrel.
Detailed description
The objective of this project is to distinguish genetic profiles that will assist a practitioner in determining the right dose or alternate medication for the patient. In partnership with the genetics team of the Avera Institute for Human Genetics and physicians with the Avera Heart Hospital of South Dakota and North Central Heart Institute, the research team will perform genetic analysis to identify genetic variances.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | Pharmacogenomics | Utilizing pharmacogenomics to determine the most effective treatment |
Timeline
- Start date
- 2012-06-01
- Primary completion
- 2015-01-01
- Completion
- 2015-01-01
- First posted
- 2012-06-05
- Last updated
- 2015-06-11
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01611545. Inclusion in this directory is not an endorsement.